PDF(Pubmed)
Abstract：
Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with NSCLC harboring EGFR fusion mutations (EGFR-MACF1 and EGFR-GNAT3) combined with EGFR amplification. Both patients received EGFR-TKI treatment, and 1 of them showed an antitumor response.
摘要：
鉴于它们良好的抗肿瘤作用，表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）是EGFR敏感突变的标准一线治疗，包括外显子19缺失和外显子21L858R突变。EGFR融合突变和EGFR扩增在非小细胞肺癌（NSCLC）中非常罕见。我们描述了2例EGFR融合突变（EGFR-MACF1和EGFR-GNAT3）合并EGFR扩增的NSCLC患者。两名患者均接受EGFR-TKI治疗，其中1例显示抗肿瘤反应。
